


CDK2-IN-41

Cat. No.:	HY-172153
Molecular Formula:	C ₁₉ H ₂₁ N ₃ S
Molecular Weight:	323.46
Target:	CDK; Reactive Oxygen Species; Apoptosis
Pathway:	Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	CDK2-IN-41 (Compound 7a) is a CDK2 inhibitor that exerts anticancer activity by binding to CDK2, thereby inhibiting the cell cycle, inducing cytotoxicity, promoting ROS production, and triggering Apoptosis. CDK2-IN-41 exhibits an IC ₅₀ of 10 μM against acute myeloid leukemia (AML) HL-60 cells. It holds potential for research in AML-related cancer therapy ^[1] .
IC₅₀ & Target	CDK2

REFERENCES

[1]. Ananta, et al. Design, Synthesis, and Simulation of Functionalized 1, 2, 3, 4-Tetrahydroisoquinolines to Treat Acute Leukemia Cells[J]. ChemistrySelect, 2025, 10(7): e202404024.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite F, Monmouth Junction, NJ 08852, USA